Tmunity Therapeutics

Founded 2015 · CIK 0001661702 · Biotech · Acquired

Armored CAR-T cell therapies that overcome immunosuppression in solid tumors

tmunity.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$140M
5 Form D · Oct 2019
83 months since last filing
Contracts
—
No federal contracts on record
Patents
12
0 granted · 12 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$4,999,998
Private capital raisedForm D · SEC$49,999,999
Private capital raisedForm D · SEC$74,999,948
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2219KINETIQ THERAPEUTICS LLC——
2220Immuneering Corp—$77M
2221Pheast Therapeutics—$50M
2222Tmunity Therapeutics—$140M
2223Alloy Therapeutics—$147M
2224ArriVent Biopharma—$191M
2225MOBIUS SCIENTIFIC INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 18 related persons
  • USMAN AZAMDirector · Executive Officer
  • GRAEME BELLExecutive Officer
  • Anne ChewDirector · Executive Officer
  • ANNE CHEWDirector
  • MICHAEL CHRISTIANOExecutive Officer
  • CHRISTINA COUGHLINExecutive Officer
  • PATRICK GRAYDirector
  • MOJI JAMESExecutive Officer
  • JASON KRENTZExecutive Officer
  • JUDITH LIDirector
  • Kevin MahoneyDirector
  • KEVIN MAHONEYDirector
  • GARRY NICHOLSONDirector
  • SEAN PARKERDirector
  • ALESSANDRO RIVADirector
  • BETH SEIDENBERGDirector
  • JIANG ZHANGDirector
  • YAN ZHANGDirector

Patents

USPTO · 0 granted of 12
  • Vector-free Process For Manufacture Of Engineered Immune Cellsapplication
  • Methods For Producing Clinical-grade Lentiviral Vectorapplication
  • Alternative Generation Of Allogeneic Human T Cellsapplication
  • Adoptive Cell Therapy And Methods Of Dosing Thereofapplication
  • Methods For Producing Clinical-grade Lentiviral Vectorapplication
  • DNVSIG3 And DNVSIG8 Receptors And Methos Of Using The Sameapplication
  • Adoptive Cell Therapy And Methods Of Dosing Thereofapplication
  • Vector-free Process For Manufacture Of Engineered Immune Cellsapplication
  • Methods For Producing Clinical-grade Lentiviral Vectorapplication
  • Large Scale Car-t Immune Cell Manufacturing Method Utilizing Lentiviral Vector Transfectionapplication
  • Alternative Generation Of Allogeneic Human T Cellsapplication
  • Vector-free Process For Manufacture Of Engineered Immune Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.